BSX Q2 2025 Earnings Transcript

Boston Scientific posted Q2 revenue of $5.061 billion, up 22.8% reported and 17.4% organic, with adjusted EPS of $0.75 beating guidance and adjusted operating margin expanding 50 bps to 27.6%. The company raised full-year organic growth guidance to 14%-15% from 12%-14% and maintained full-year adjusted EPS guidance of $2.95-$2.99, while lowering the tariff headwind estimate to about $100 million from $200 million. Performance was driven by strong WATCHMAN and FARAPULSE adoption, plus double-digit growth across several segments, though gross margin was pressured by ACURATE valve discontinuation charges.

Analysis

BSX’s real signal is not the beat itself; it’s the mix shift into higher-conviction franchises that should compound even if headline growth decelerates. WATCHMAN + FARAPULSE + imaging are increasingly self-reinforcing: more EP installed base creates more concomitant adoption, which in turn widens the moat against lower-quality PFA entrants that can match lesion creation but not workflow integration. That matters because the margin profile should stay resilient even as management deliberately re-accelerates R&D, implying the market is likely underestimating how much operating leverage can coexist with higher spend.

The biggest second-order winner may be ASCs and hospital systems with EP capacity constraints, not just BSX. If procedures migrate outpatient, the initial case mix should skew to simpler PVI cases, which helps BSX’s volume story more than it hurts it because the company is the obvious beneficiary of workflow standardization, even if concomitant cases are delayed. Meanwhile CMS reimbursement pressure on LAAC is a near-term headline risk, but it is more likely to cap procedure economics at the margin than to derail clinical adoption; the harder issue is timing, because reimbursement lag can slow the conversion of positive clinical data into incremental volumes over the next 6-18 months.

The cleanest contrarian read is that the market may be too focused on ACURATE and tariffs, and not enough on the durability of the underlying growth engine. Those are temporary gross-margin drags; the more durable variable is whether BSX can keep expanding share in EP and coronary therapies while competitors are still monetizing older platforms. If so, BSX deserves a premium multiple on a 12-24 month view, but the stock is vulnerable to any evidence that PFA growth normalizes faster than expected or that CMS/hospital reimbursement slows concomitant monetization.

Net: this is a quality-growth compounder with a better-than-expected FY25 setup, but the next leg higher likely needs either another quarter of >15% organic growth or clearer evidence that 2026 margin expansion survives R&D reinvestment.

Key Decisions for Investors

• Go long BSX on pullbacks over the next 1-3 weeks; risk/reward favors owning the name into Investor Day because guidance upside is still underwritten by momentum, while downside from ACURATE/tariffs is now largely quantified.
• Pair trade: long BSX / short SYK for 3-6 months. BSX has the cleaner near-term growth inflection and more visible EP share gains; SYK remains higher quality, but relative multiple support looks stretched if BSX keeps printing mid-teens organic growth.
• Buy BSX Jan-2026 calls or a call spread to express upside from EP/LAAC mix and potential multiple expansion; target a 2:1 payoff if the market re-rates BSX as a durable double-digit organic grower.
• Avoid or hedge CMS exposure into the next reimbursement cycle; the proposed LAAC fee cut is a small direct P&L issue for BSX, but it is a real sentiment overhang that can slow multiple expansion in the near term.
• If BSX trades to a premium on Investor Day hype, fade with a tactical short against a healthcare basket: the stock needs continued evidence that ASC migration and concomitant attach rates accelerate, not just maintain, to justify further multiple expansion.